New compounds from acid hydrolyzed products of the fruits of Momordica charantia L. and their inhibitory activity against protein tyrosine phosphatas 1B

Zeng, Ke; He, Yanni; Yang, Di; Cao, Jiaqing; Xia, Xichun; Zhang, Shijun; Bi, Xiuli; Zhao, Yuqing

doi:10.1016/j.ejmech.2014.01.066

Cited by 30 publications

(11 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Oral administration of pumpkin extract significantly decreases blood glucose levels in STZ-induced rats and diabetic patients via the increase of insulin secretion, the increase of β-cell mass, or the inhibition of α-amylase and α-glucosidase [28, 29]. In addition, extracts of Momordica charantia reduce blood glucose levels in diabetic rats and patients via the stimulation of translocation of glucose transporter 4, the promotion of β-cell recovery, and the inhibition of protein-tyrosine phosphatase 1B [30–32]. In this study, we found that TK was the most frequently used Chinese medicinal herb in diabetic patients in Taiwan.…”

Section: Discussionmentioning

confidence: 99%

Hypoglycemic effects of Trichosanthes kirilowii and its protein constituent in diabetic mice: the involvement of insulin receptor pathway

Yang

et al. 2017

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundDiabetes is a serious chronic metabolic disorder. Trichosanthes kirilowii Maxim. (TK) is traditionally used for the treatment of diabetes in traditional Chinese medicine (TCM). However, the clinical application of TK on diabetic patients and the hypoglycemic efficacies of TK are still unclear.MethodsA retrospective cohort study was conducted to analyze the usage of Chinese herbs in patients with type 2 diabetes in Taiwan. Glucose tolerance test was performed to analyze the hypoglycemic effect of TK. Proteomic approach was performed to identify the protein constituents of TK. Insulin receptor (IR) kinase activity assay and glucose tolerance tests in diabetic mice were further used to elucidate the hypoglycemic mechanisms and efficacies of TK.ResultsBy a retrospective cohort study, we found that TK was the most frequently used Chinese medicinal herb in type 2 diabetic patients in Taiwan. Oral administration of aqueous extract of TK displayed hypoglycemic effects in a dose-dependent manner in mice. An abundant novel TK protein (TKP) was further identified by proteomic approach. TKP interacted with IR by docking analysis and activated the kinase activity of IR. In addition, TKP enhanced the clearance of glucose in diabetic mice in a dose-dependent manner.ConclusionsIn conclusion, this study applied a bed-to-bench approach to elucidate the hypoglycemic efficacies and mechanisms of TK on clinical usage. In addition, we newly identified a hypoglycemic protein TKP from TK. Our findings might provide a reasonable explanation of TK on the treatment of diabetes in TCM.

show abstract

Section: Discussionmentioning

confidence: 99%

Hypoglycemic effects of Trichosanthes kirilowii and its protein constituent in diabetic mice: the involvement of insulin receptor pathway

Yang

et al. 2017

BMC Complement Altern Med

View full text Add to dashboard Cite

show abstract

“…Further in a 2014 study, Zeng et al [44] reported the isolation of four new cucurbitane-type sapogenins together with eight known compounds from the acid-hydrolyzed fruit extracts of M.charantia . On screening for their biological activity, these compounds showed significant inhibition of a tyrosine phosphatase, protein tyrosinephosphatase 1B (PTP1B), which is implicated in type II diabetes.…”

Section: Bioassay Guided Fractionations Of Bitter Melon (M Charanmentioning

confidence: 99%

Promise of bitter melon ( Momordica charantia ) bioactives in cancer prevention and therapy

Raina

Kumar

Agarwal

2016

Seminars in Cancer Biology

View full text Add to dashboard Cite

Recently, there is a paradigm shift that the whole food-derived components are not ‘idle bystanders’ but actively participate in modulating aberrant metabolic and signaling pathways in both healthy and diseased individuals. One such whole food from Cucurbitaceae family is ‘bitter melon’ (Momordica charantia, also called bitter gourd, balsam apple, etc.), which has gained an enormous attention in recent years as an alternative medicine in developed countries. The increased focus on bitter melon consumption could in part be due to several recent pre-clinical efficacy studies demonstrating bitter melon potential to target obesity/type II diabetes-associated metabolic aberrations as well as its pre-clinical anti-cancer efficacy against various malignancies. The bioassay-guided fractionations have also classified the bitter melon chemical constituents based on their anti-diabetic or cytotoxic effects. Thus, by definition, these bitter melon constituents are at cross roads on the bioactivity parameters; they either have selective efficacy for correcting metabolic aberrations or targeting cancer cells, or have beneficial effects in both conditions. However, given the vast, though dispersed, literature reports on the bioactivity and beneficial attributes of bitter melon constituents, a comprehensive review on the bitter melon components and the overlapping beneficial attributes is lacking; our review attempts to fulfill these unmet needs. Importantly, the recent realization that there are common risk factors associated with obesity/type II diabetes-associated metabolic aberrations and cancer, this timely review focuses on the dual efficacy of bitter melon against the risk factors associated with both diseases that could potentially impact the course of malignancy to advanced stages. Furthermore, this review also addresses a significant gap in our knowledge regarding the bitter melon drug-drug interactions which can be predicted from the available reports on bitter melon effects on metabolism enzymes and drug transporters. This has important implications, given that a large proportion of individuals, taking bitter melon based supplements/phytochemical extracts/food based home-remedies, are also likely to be taking conventional therapeutic drugs at the same time. Accordingly, the comprehensively reviewed information here could be prudently translated to the clinical implications associated with any potential concerns regarding bitter melon consumption by cancer patients.

show abstract

“…Dentre as espécies vegetais utilizadas, o melão-de-São-Caetano (Momordica charantia L.) é classificado como uma planta daninha com incidência Research, Society and Development, v. 9, n. 7, e15973769, 2020 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v9i7.3769 frequente em pomares, cercas, hortas, cafezais, alambrados e terrenos baldios (Lorenzi, 2000). É usado na alimentação e em atividades farmacológicas como anti-hiperglicêmico (Rao, et al, 2001), antidiabético (Zhang, et al, 2014), antifúngico (Alam, et al, 2009), efeitos antioxidantes (Shan, et al, 2012;Panda, et al, 2015), atividades citotóxicas (Zhang, et al, 2014) e inibidoras da proteína tirosina fosfatas 1 B (Zeng, et al, 2014).…”

Section: Introductionunclassified

Momordica charantia L. no tratamento de diabetes melittus

Cruz

Freire

Pereira

et al. 2020

RSD

View full text Add to dashboard Cite

Introduction: Drugs of plant origin have been used since ancient times. The use of medicinal plants in disease control has grown due to therapeutic feasibility and successful clinical cases. Some plant species are used to combat the symptoms caused by diabetes mellitus in association or not with traditional medicine, among them, the São Caetano melon (Momordica charantia L.). Objective: The objective of this literature review is to analyze the main researches on the use of M. charantia L. in the treatment of diabetes mellitus. Methodology: The work consists of an integrative literature review based on original articles in the English language from the Google Scholar, Oxford Academic, Science Direct, Taylor & Francis and Web of Science databases. Results: Of the 31 articles selected for the research, only 5 were used (16.13%). It was observed that in the 5 articles used, M. charantia L. reduced glycemic levels, as well as providing other benefits. Conclusion: The prophylactic use of M. charantia L. is an alternative in the treatment of diabetes mellitus, as well as other diseases.

show abstract

New compounds from acid hydrolyzed products of the fruits of Momordica charantia L. and their inhibitory activity against protein tyrosine phosphatas 1B

Cited by 30 publications

References 27 publications

Hypoglycemic effects of Trichosanthes kirilowii and its protein constituent in diabetic mice: the involvement of insulin receptor pathway

Hypoglycemic effects of Trichosanthes kirilowii and its protein constituent in diabetic mice: the involvement of insulin receptor pathway

Promise of bitter melon ( Momordica charantia ) bioactives in cancer prevention and therapy

Momordica charantia L. no tratamento de diabetes melittus

Contact Info

Product

Resources

About